HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Asciminib and ponatinib combination in Philadelphia chromosome-positive acute lymphoblastic leukemia.

AuthorsJérémie Zerbit, Jerome Tamburini, Lauriane Goldwirt, Justine Decroocq, Jean Michel Cayuela, Nicolas Chapuis, Adrien Contejean, Rui Batista, Didier Bouscary, Lise Willems
JournalLeukemia & lymphoma (Leuk Lymphoma) Vol. 62 Issue 14 Pg. 3558-3560 (12 2021) ISSN: 1029-2403 [Electronic] United States
PMID34405773 (Publication Type: Letter)
Chemical References
  • Imidazoles
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyridazines
  • asciminib
  • Niacinamide
  • ponatinib
  • Fusion Proteins, bcr-abl
Topics
  • Fusion Proteins, bcr-abl (genetics)
  • Humans
  • Imidazoles
  • Niacinamide (analogs & derivatives)
  • Philadelphia Chromosome
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma (diagnosis, drug therapy, genetics)
  • Protein Kinase Inhibitors (adverse effects)
  • Pyrazoles
  • Pyridazines (adverse effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: